Maekmoondong-tang in treatment of postoperative cough in patients with lung cancer

Cheon, Chunhoo; Kang, Sohyeon; Ko, Youme; Kim, Mia; Jang, Bo‐Hyoung; Shin, Yong‐Cheol; Ko, Seong‐Gyu

doi:10.1097/md.0000000000011541

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 31 , 32 ] In Korea, studies were conducted to evaluate the efficacy of herbal medicines on fatigue, radiation dermatitis, sleep disturbance, anorexia, and cough in patients with cancer. [ 33 – 38 ] These studies used licensed herbal medicines for patients with cancer. This study is a clinical trial of a new herbal medicine for the treatment of cancer patients, which has been rarely performed in Korea.…”

Section: Discussionmentioning

confidence: 99%

Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer

Cheon

Ko²

2020

Medicine

Self Cite

View full text Add to dashboard Cite

Introduction: Cancer is the second leading cause of death, and the burden of cancer continues to grow globally. Research on the efficacy of combined administration of herbal medicine and anticancer drugs is also increasing. SH003 is a new herbal medicine composed of Astragalus membranaceus , Angelica gigas , and Trichosanthes kirilowii . SH003 alone up to 4800 mg daily was found to be safe. Preclinical studies have shown SH003 to have a synergistic effect with coadministration of anticancer drugs. This study aimed to determine the maximum tolerated dose of SH003 combined with docetaxel in patients with lung or breast cancer. Methods: This is an open-label, dose-escalation study to evaluate the safety of SH003 combined with docetaxel. Patients with lung or breast cancer will be recruited. The participants will be divided into 3 groups based on SH003 daily dose (2400, 3600, and 4800 mg); the medication will be taken orally for 21 days. The traditional 3 + 3 design will be adopted for the dose escalation. Dose-limiting toxicities are defined as grade 3 or 4 adverse events according to the Common Terminology Criteria for Adverse Events. The highest dose at which no more than 1 of the 6 patients experience dose-limiting toxicity will be determined as the maximum tolerated dose of SH003 combined with docetaxel. Discussion: This study investigates the safety of SH003 when combined with docetaxel. The results of this study will provide a safe dose range for conducting therapeutic exploratory trials. Trial registrations: ClinicalTrials.gov NCT04360317.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer

Cheon

Ko²

2020

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Postoperative cough may be related to mediastinal lymphadenectomy, diaphragm elevation, reduced lung volume, and gastroesophageal re ux, as well as other anatomical factors. [33]. The group receiving STM intervention showed better cough symptom control than did usual care for patients.…”

Section: Effects On the Coughmentioning

confidence: 93%

Effects of a symptom cluster management intervention on the symptom cluster of pain-cough-fatigue-shortness of breath-anorexia and quality of life among post-thoracoscopic-surgery patients with lung cancer: A randomized controlled trial

Wang,

Liu,

Duan

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To construct a symptom cluster management intervention based on symptom cluster theory for patients with non-small cell lung cancer (NSCLC) undergoing 3D thoracoscopic lobectomy and evaluate the efficacy and feasibility of the intervention on a five-symptom cluster, including pain, cough, fatigue, shortness of breath, anorexia, and quality of life (QoL) and hospital stay time of patients with lung cancer in the early period after lung cancer surgery. Methods A total of 100 patients with NSCLC after surgery from a hospital in a city in northern China from October 2019 to December 2019 were randomly assigned to either the intervention group (N = 50) or the control group (N = 50). The participants in the intervention group received symptom cluster management intervention based on the symptom management theory, while the control group received only usual care. The study outcomes, including pain, cough, shortness of breath, anorexia, fatigue, and QoL, were evaluated at baseline and on the first and fourth postoperative days. Results The baseline characteristic was comparable between the two groups. Pain, daytime cough, nighttime cough, fatigue, and shortness of breath were similar in both groups on the first postoperative day (all P > 0.05). Compared with the control group, the intervention group reported less pain, cough, fatigue, shortness of breath, and anorexia and more QoL on the fourth postoperative day, and shorter postoperative hospital stay time (all P < 0.05). Conclusion The symptom management intervention appears to be a feasible and acceptable method to manage the five-symptom cluster, promote QoL, and reduce postoperative hospital stay time in patients with NSCLC. Future studies are needed to examine the long-term effects of this intervention. Trial registration This study is retrospectively registered at Chinese Clinical Trial Registry (ChiCTR2300076312).

show abstract

Factors and potential treatments of cough after pulmonary resection: A systematic review

Zhang

et al. 2021

Asian Journal of Surgery

View full text Add to dashboard Cite

Maekmoondong-tang in treatment of postoperative cough in patients with lung cancer

Cited by 4 publications

References 13 publications

Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer

Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer

Effects of a symptom cluster management intervention on the symptom cluster of pain-cough-fatigue-shortness of breath-anorexia and quality of life among post-thoracoscopic-surgery patients with lung cancer: A randomized controlled trial

Factors and potential treatments of cough after pulmonary resection: A systematic review

Contact Info

Product

Resources

About